Good distribution practice (GDP) describes the minimum standards that a wholesale distributor must meet to ensure that the quality and integrity of medicines is maintained throughout the supply chain.
Compliance with GDP ensures that:
- medicines in the supply chain are authorised in accordance with European Union (EU) legislation;
- medicines are stored in the right conditions at all times, including during transportation;
- contamination by or of other products is avoided;
- an adequate turnover of stored medicines takes place;
- the right products reach the right addressee within a satisfactory time period.
The distributor should also put in place a tracing system to enable finding faulty products and an effective recall procedure.
GDP also applies to the sourcing, storage and transportation of active pharmaceutical ingredients and other ingredients used in the production of the medicines.
The Agency's work involves harmonisation of GDP activities at an EU level, including:
- coordinating the preparation of new and revised guidance on GDP;
- developing EU-wide procedures relating to GDP inspections.
Legal framework and guidelines
In addition, two European Commission guidelines establish the requirements of GDP:
- Guidelines on GDP of medicinal products for human use
- Guidelines on principles of GDP for active substances for medicinal products for human use
Wholesale distribution authorisation
Anyone engaged in the activity of wholesale distribution of medicinal products in the EEA must hold a wholesale distribution authorisation issued by the national competent authority of the Member State where they carry out these activities. The same national authority is responsible for inspecting the wholesale distributer.
Wholesale distributors must comply with EU GDP to obtain a wholesale distribution authorisation. They can ensure that they meet all their legal obligations by following the GDP guidelines.
Manufacturing authorisation holders do not require a separate authorisation to distribute products that are already subject to a manufacturing authorisation.
Importers and distributors of active substances intended for the manufacture of medicines in the EEA are obliged to register with the relevant national competent authority and comply with the principles of GDP for active substances.
Parallel distributors also must comply with GDP. For more information, see Parallel distribution.
EudraGMDP is a publicly accessible EU database containing all wholesale distribution authorisations and details of registered importers and distributors of active substances in the EEA.
After inspecting a wholesale distributer, EU competent authorities issue a GDP certificate or a non-compliance statement, which is entered in the EudraGMDP database.
EudraGMDP also contains information relating to good manufacturing practice (GMP).
GMP/GDP Inspectors Working Group
EMA coordinates the GMP/GDP Inspectors Working Group of senior inspectors appointed by all EEA competent authorities. It meets at EMA four times a year.
The group provides a forum for harmonisation and discussion of common issues, such as updates or amendments to the EU GDP guidelines and the compilation of Union procedures.
Compilation of Union procedures
EMA maintains a compilation of GDP and GMP inspection-related procedures and forms agreed by all Member States. This facilitates cooperation between EU Member States and supports harmonisation and exchange of inspection-related information.
It covers how quality defects and non-compliance are handled and how GMP and GDP inspections are carried out and reported:
EMA published the Word version of some of the templates for the convenience of inspectorates:
- Rapid alert notification of a quality defect / recall
- Follow-up and non-urgent information for quality defects
How useful is this page?
Average rating:Based on 6 ratings
Add your rating:
- See all ratings
1 ratings0 ratings0 ratings0 ratings5 ratings